Share This Article:

Giant 10 cm Diameter Esophageal Gastrointestinal Stromal Tumor (GIST)

Abstract Full-Text HTML XML Download Download as PDF (Size:3213KB) PP. 177-180
DOI: 10.4236/wjcs.2014.411025    3,270 Downloads   3,880 Views  

ABSTRACT

Gastrointestinal stromal tumor (GIST) is a relatively rare type of cancer that affects an estimated 5000 to 10,000 new people each year in the US. Most GIST tumors develop in the stomach; but they can also arise in the small intestine, colon and rectum, esophagus or abdominal cavity. Gastrointestinal stromal tumors are the most common mesenchymal, nonepithelial tumors of the gastrointestinal tract in adults between 40 and 50 years of age. Esophageal GIST, in contrast, is rare, amounting to 12.7% - 28% of mesenchymal esophageal tumors or 2% of all GISTs and their diagnosis and management are still challenging, as illustrated in the following case. However here we report a rare case of a 43-year-old female patient who was referred to our department complaining with a 1-month history of atypical chest pain and productive cough. A chest computed tomographic scan and endoscopic ultrasound revealed a submucosal esophageal tumor measuring 100 × 80 × 40 mm in its largest diameter, we performed enucleation via left thoracotomy.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

Simoglou, C. , Mikroulis, D. , Konstantinou, F. and Bougioukas, G. (2014) Giant 10 cm Diameter Esophageal Gastrointestinal Stromal Tumor (GIST). World Journal of Cardiovascular Surgery, 4, 177-180. doi: 10.4236/wjcs.2014.411025.

References

[1] Demetri, G.D., Mehren, M. and Blake, C.D. (2002) Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors. The New England Journal of Medicine, 347, 472-480.
http://dx.doi.org/10.1056/NEJMoa020461
[2] Aparicio, T., Boige, V. and Sabourin, J.C. (2004) Prognostis Factors after Surgery of Primary Resectable Gastrointestinal Stromal Tumours. European Journal of Surgical Oncology, 30, 1098.
http://dx.doi.org/10.1016/j.ejso.2004.06.016
[3] Heinrich, M.C., Rubin, B.P., Longely, B.J. and Fletcher, J.A. (2002) Biology and Genetic Aspects of Gastrointestinal Stromal Tumours: KIT Activation and Cytogenetic Alterations. Human Pathology, 33, 484-495.
[4] Choi, W.H., Kim, S., Hyung ,W.J., Yu, J.S., Park, C.I., Choi, S.H. and Noh, S.H. (2009) Long-Surviving Patients with Recurrent GIST after Receiving Cytoreductive Surgery with Imatinib Therapy. Yonsei Medical Journal, 50, 437-447.
http://dx.doi.org/10.3349/ymj.2009.50.3.437
[5] Zhu, J., Wang, Y., Hou, M., Li, H.Y. and Zhang, J. (2007) Imatinib Mesylate Treatment for Advanced Gastrointestinal Stromal Tumor: A Pilot Study Focusing on Patients Experiencing Sole Liver Metastasis after a Prior Radical Resection. Oncology, 73, 324-327.
http://dx.doi.org/10.1159/000134475

  
comments powered by Disqus

Copyright © 2019 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.